5 results
Study Objectives:* To monitor the long-term safety profile of NI-0501* To assess HLH patients* survival after NI-0501 treatment* To assess duration of response to NI-0501 treatment (i.e. maintenance of HLH control)* To assess post-HSCT outcome…
The proportion of patients in GC-free remission after 20 weeks.
The aim of this study is to investigate how safe, effective, and well-tolerated multiple infusions of the experimental study treatment, emapalumab (the study medication) are in controlling this disease, as well as to check the concentrations of…
The aim of this study is to investigate non-inferiority of rituximab SC 336 mg to rituximab IV 200 mg.
Primary objective: To demonstrate efficacy of emapalumab in the treatment of patients in:• Cohort 1: Macrophage activation syndrome (MAS) in the context of systemic juvenile idiopathic arthritis (sJIA) and adult onset Still*s disease (AOSD).• Cohort…